MED-EL儿童人工耳蜗扩展适应症的多中心研究结果
这项多中心、非随机、单受试者重复测量研究评估了MED-EL人工耳蜗在12个月以下儿童及12-71个月有残余听力儿童中的安全性和有效性。前瞻性队列38例(26例<12个月)和回顾性队列209例(70例<12个月)中,80.6%前瞻性和88.0%回顾性受试者在激活后12个月达到言语识别或听觉技能发展目标,支持将儿童人工耳蜗适应症扩展至7-11个月重度感音神经性聋及12-71个月有残余听力儿童。
要点
- 80.6%前瞻性和88.0%回顾性受试者在12个月达到性能目标
- 回顾性队列达到主要疗效终点(95%CI 79.6%-93.9%,p=0.002)
- 严重不良设备事件在<6%受试者中发生,无意外不良事件
核心结论
- 结果提示将儿童人工耳蜗适应症扩展至7-11个月重度感音神经性聋及12-71个月有残余听力儿童是合适的。
研究设计与样本
- 多中心、非随机、单受试者重复测量研究,含前瞻性队列38例(26例<12个月)和回顾性队列209例(70例<12个月)。
- 所有受试者在6岁前接受MED-EL人工耳蜗,前瞻性38例中36例、回顾性209例中92例有疗效数据。
主要发现
- <12个月亚组:前瞻性25例中21例(84.0%)、回顾性37例中32例(86.5%)达到目标。
- 12-71个月有残余听力亚组:前瞻性6例中6例、回顾性34例中30例(88.2%)达到目标。
- 回顾性队列达到主要疗效终点(95%CI:79.6%,93.9%;p=0.002),前瞻性样本量不足以进行假设检验。
- 前瞻性9例和回顾性33例受试者发生任何不良设备事件,严重不良设备事件在<6%受试者中发生,无意外不良设备事件。
关键数值与推荐
- 主要疗效终点假设≥75%受试者在激活后12个月达到研究特定的言语识别或听觉技能发展性能目标。
- 主要安全终点为不良设备事件(ADEs)。
临床怎么用
- 考虑将MED-EL儿童人工耳蜗适应症扩展至7-11个月重度感音神经性聋儿童及12-71个月有残余听力儿童。
局限性
- 前瞻性样本量太小,无法进行假设检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To demonstrate safety and efficacy of MED-EL cochlear implants (CIs) in children aged < 12 months and in children aged 12-71 months with residual hearing. METHODS: This was a multicenter, nonrandomized, single-subject, repeated-measures study with prospective (N = 38; 26 < 12 months of age) and retrospective (N = 209; 70 < 12 months of age) arms. All subjects received MED-EL CIs before age 6 and had safety data for analysis. Thirty-six of 38 prospective and 92 of 209 retrospective subjects had efficacy data available for analysis. Primary efficacy endpoint hypothesized that ≥ 75% of subjects would meet study-specific performance goals on speech recognition or auditory skill development measures by 12 months post-activation. Primary safety endpoint was adverse device effects (ADEs). RESULTS: Twenty-nine of 36 prospective (80.6%) and 81 of 92 retrospective (88.0%) subjects with 12-month efficacy data met endpoint performance goals. This included 21 of 25 (84.0%) prospective and 32 of 37 (86.5%) retrospective subjects < 12 months old and 6 of 6 prospective and 30 of 34 (88.2%) retrospective subjects 12-71 months old with residual hearing. Prospective sample size was too small for hypothesis testing, but the retrospective cohort met the primary efficacy endpoint (95% CI: 79.6%, 93.9%; p = 0.002). Nine prospective and 33 retrospective subjects experienced any ADE, including serious ADEs (SADEs) in < 6% of subjects. No unanticipated ADEs. CONCLUSION: Results suggest that it is appropriate to expand pediatric CI indications to include children aged 7-11 months with profound sensorineural hearing loss (SNHL) and children aged 12-71 months with residual hearing.
引用
- Young NM, Thomas D, Hoff SR, et al. Multicenter Study Results on Expanded Indications in Med-EL Pediatric Cochlear Implant Population. Laryngoscope. 2026. PMID: 42619050. doi:10.1002/lary.70840
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。